News
Merck shells out $10 billion for Verona
Digest more
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
Merck announces plans of buying Verona for a huge premium. VRNA deal could shield Merck from two major headwinds.
See the latest Merck & Co Inc stock price (MRK:XNYS), related news, valuation, dividends and more to help you make your investing decisions.
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...
Explore more
2d
Barchart on MSNWhat You Need To Know Ahead of Merck's Earnings ReleaseMerck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results